No connection

Search Results

IPHA vs UNH

IPHA
Innate Pharma S.A.
BEARISH
Price
$1.41
Market Cap
$132.2M
Sector
Healthcare
AI Confidence
90%
UNH
UnitedHealth Group Incorporated
NEUTRAL
Price
$323.48
Market Cap
$293.61B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
IPHA
--
UNH
24.43
Forward P/E
IPHA
-2.25
UNH
16.08
P/B Ratio
IPHA
-5.18
UNH
3.11
P/S Ratio
IPHA
14.69
UNH
0.66
EV/EBITDA
IPHA
-2.29
UNH
16.47

Profitability

Gross Margin
IPHA
0.0%
UNH
18.53%
Operating Margin
IPHA
-689.55%
UNH
0.34%
Profit Margin
IPHA
0.0%
UNH
2.69%
ROE
IPHA
--
UNH
12.54%
ROA
IPHA
-38.85%
UNH
3.9%

Growth

Revenue Growth
IPHA
-46.7%
UNH
12.3%
Earnings Growth
IPHA
--
UNH
-99.9%

Financial Health

Debt/Equity
IPHA
--
UNH
0.82
Current Ratio
IPHA
1.27
UNH
0.79
Quick Ratio
IPHA
1.14
UNH
0.7

Dividends

Dividend Yield
IPHA
--
UNH
2.73%
Payout Ratio
IPHA
0.0%
UNH
65.99%

AI Verdict

IPHA BEARISH

IPHA exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a negative Price-to-Book ratio of -5.18, indicating negative shareholder equity. The company is experiencing a collapse in top-line growth with revenue declining 46.7% YoY, coupled with an unsustainable operating margin of -689.55%. While analysts maintain a 'strong_buy' rating with a $6.00 target, this is fundamentally disconnected from the current data-driven trajectory of value destruction and operational losses.

Strengths
Strong analyst consensus (Strong Buy) suggesting potential pipeline value not captured in financials
Current ratio of 1.27 provides a minimal short-term liquidity cushion
Recent slight 1-week price recovery (+2.9%)
Risks
Negative Book Value (P/B -5.18) indicating insolvency or severe capital erosion
Catastrophic operating margins (-689.55%)
Significant revenue contraction (-46.7% YoY)
UNH NEUTRAL

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.

Strengths
Strong consistent revenue growth (12.3% YoY)
Manageable Debt/Equity ratio of 0.82
Attractive Forward P/E (16.08) compared to current P/E (24.43)
Risks
Extreme earnings volatility (YoY Earnings Growth -99.9%)
Poor liquidity indicated by a Current Ratio of 0.79
Extremely thin operating margins (0.34%)

Compare Another Pair

IPHA vs UNH: Head-to-Head Comparison

This page compares Innate Pharma S.A. (IPHA) and UnitedHealth Group Incorporated (UNH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile